Acalabrutinib in CLL/SLL Survival Expectation: ELEVATE-TN and ASCEND Long-Term PFS, OS

　　1.Why there is no single survival timeframe

　　Acalabrutinib is a BTK inhibitor for CLL,SLL,and selected B-cell lymphoid malignancies.How long a patient lives depends on age at diagnosis,Binet/Rai stage,tumor burden,TP53 mutation or del(17p),IGHV mutation status,complex karyotype,number of prior lines,relapsed/refractory status,and long-term risks such as infection,bleeding,second primary malignancy,and cardiotoxicity.Instead of estimating“extra years”from monotherapy duration,clinicians use progression-free survival(PFS),overall survival(OS),response depth,and minimal residual disease.

　　2.Treatment-naive CLL/SLL:ELEVATE-TN long-term data

　　ELEVATE-TN randomized 535 treatment-naive CLL patients to acalabrutinib plus obinutuzumab,acalabrutinib monotherapy,or obinutuzumab plus chlorambucil.At median follow-up about 74.5 months:

　　72-month PFS was about 78.0%with A+O,61.5%with acalabrutinib alone,and 17.2%with chemoimmunotherapy;median PFS was not reached for both acalabrutinib arms and 27.8 months for control.

　　72-month OS was about 83.9%,75.5%,and 74.7%;median OS was not reached in any arm.A+O showed significantly longer OS than control(HR about 0.62),while monotherapy OS was affected by crossover after control progression.

　　High-risk subgroups with unmutated IGHV,del(17p)and/or TP53 mutation,or complex karyotype had better PFS with acalabrutinib regimens;in del(17p)/TP53 subgroup,72-month PFS was about 56%for both acalabrutinib arms versus 18%for control.

　　Interpretation:many treatment-naive patients maintain progression-free disease for years,but individual OS cannot be promised as 3,5,or 10 extra years.Combination gives deeper response and longer PFS;monotherapy may favor tolerability and convenience.

　　3.Relapsed or refractory CLL:ASCEND long-term data

　　ASCEND enrolled 310 relapsed/refractory CLL patients to acalabrutinib 100mg twice daily versus investigator’s idelalisib plus rituximab or bendamustine plus rituximab.At median follow-up about 46.5 months:

　　Median PFS was not reached with acalabrutinib versus 16.8 months with control;42-month PFS about 62%versus 19%.

　　42-month OS about 78%versus 65%;median OS not reached in either arm;progression or death risk reduced about 72%.

　　PFS benefit persisted in del(17p)and/or TP53 mutation and unmutated IGHV subgroups,but OS advantage was not significant in the TP53/del(17p)subgroup,supporting early re-biopsy,mutation reassessment,and combination or sequential planning.

　　4.Applying group data to an individual

　　Do not treat cohort percentages as personal prognosis.Review CBC and nodal response at 3–6 months;complete FISH,TP53/17p,IGHV,and relevant mutation panel by 6–12 months;reassess PFS every 6–12 months during continuous therapy.For progression,severe infection,major bleeding,atrial fibrillation/heart failure,hepatotoxicity,or poor tolerance,a hematologist may hold,reduce,switch BTK inhibitor,add a BCL2 inhibitor,or refer to clinical trials.

　　5.Patient communication

　　Acalabrutinib is better framed as prolonging progression-free control and preserving treatment options than as a fixed survival extension.Younger low-risk patients without TP53 alterations may sustain long monotherapy or post-combination maintenance;older multi-relapsed patients with TP53/del(17p)need closer monitoring for progression and infection.Never stop or change therapy without specialist review.